Securities & Investment Fraud

Clover Health Investments, Corp. Securities Class Litigation

Introduction

Securities class action litigation has been filed on behalf of investors in the securities of Clover Health Investments, Corp. (“Clover” or the “Company”) (NASDAQ: CLOV). If you purchased Clover securities between October 6, 2020 and February 4, 2021, inclusive (the “Class Period”), including purchases or acquisitions of Clover securities pursuant or traceable to the Company’s registration statement and prospectus in connection with its merger with Social Capital Hedosophia Holdings Corp. III (“SCH”) in or around December 2020, you may move the court for appointment as lead plaintiff by no later than April 6, 2021.

You may retain Lieff Cabraser Heimann & Bernstein, LLP, or other attorneys, as your counsel in the action.  Recognized by the National Law Journal as one of the nation’s top plaintiffs’ law firms, Lieff Cabraser is committed to safeguarding the rights of investors and upholding the integrity of the market.  We have significant experience and a successful track record of representing institutional and individual investors in securities and financial fraud litigation.

Clover investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should use the form below or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Clover Securities Class Litigation

Clover, headquartered in Franklin, Tennessee, is a health insurance services company that primarily provides Medicare Advantage healthcare plans for seniors.  On January 7, 2021, Clover merged with SCH, a publicly listed special-purpose acquisition company, and began to trade under the symbol “CLOV.”    The action alleges that, during the Class Period, defendants made false and/or misleading statements and failed to disclose to investors that (1) Clover’s Clover Assistant platform was under active investigation by the Department of Justice (“DOJ”) for at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals; (2) the DOJ’s investigation presented a risk to the Company, since it derives most of its revenues from Medicare; (3) Clover’s sales were driven by a major undisclosed related party deal and misleading marketing targeting the elderly, not its purported “best-in-class” technology; and (4) a significant portion of Clover’s sales were derived from an undisclosed relationship between Clover and an outside brokerage firm controlled by Clover’s Head of Sales.

On February 4, 2021, Hindenburg Research published a report revealing the existence of an active DOJ investigation of the Company for issues including kickbacks, marketing practices, undisclosed third-party deals, and Clover’s software “Clover Assistant” that purportedly serves “low-income and often overlooked communities.”  On this news, Clover’s stock price fell $1.72, or approximately 12.3%, from its closing price of $13.95 on February 3, 2021, to close at $12.23 on February 4, 2021.

The following day, on February 5, 2021, Clover disclosed that it was aware of the DOJ investigation prior to its merger with SCH, and that it had received an inquiry from the U.S. Securities and Exchange Commission following publication of Hindenburg’s report.

Shareholder Contact Form


    First Name (required)

    Last Name (required)

    Email address (required)

    Street Address

    City

    State

    Zip

    Telephone

    How did you find our site?

    Are you currently represented by an attorney?

    II.TRANSACTIONS IN CLOVER SECURITIES

    Number of shares of Clover securities held immediately before the start of Class Period on October 6, 2020:

    From October 6, 2020 through February 4, 2021, inclusive, I made the following transactions in Clover securities:

    PURCHASES

    Date
    No. of Shares
    Price

    show more rows

    SALES

    Date
    No. of Shares
    Price

    show more rows

    During the 90 days after February 4, 2021, I made the following transactions in Clover securities:

    PURCHASES

    Date
    No. of Shares
    Price

    show more rows

    SALES

    Date
    No. of Shares
    Price

    show more rows

    Comments & questions:

    Please sign me up for your Consumer Law newsletter. Yes


    About Lieff Cabraser

    Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Munich, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

    The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” Benchmark Litigation has named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America.”